Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

65.40
+0.99001.54%
Volume:893.79K
Turnover:58.14M
Market Cap:12.64B
PE:172.57
High:65.57
Open:64.41
Low:63.57
Close:64.41
52wk High:70.98
52wk Low:49.26
Shares:193.27M
Float Shares:192.12M
Volume Ratio:0.55
T/O Rate:0.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3790
EPS(LYR):1.80
ROE:1.18%
ROA:3.26%
PB:2.00
PE(LYR):36.33

Loading ...

Biomarin Pharmaceutical Outlook FY Revenue USD 3,875-3,925 Million

THOMSON REUTERS
·
Aug 07

Biomarin Pharmaceutical Inc Fy2026 Shr View $3.64, REV View $3.87 Bln

THOMSON REUTERS
·
Aug 07

Biomarin Pharmaceutical Q2 EPS USD 0.23

THOMSON REUTERS
·
Aug 07

BioMarin Pharmaceutical Inc Expected to Post Earnings of 69 Cents a Share - Earnings Preview

Reuters
·
Aug 05

Spruce Biosciences Names Jessica Cohen Pfeffer Vice President, Clinical Development

Reuters
·
Aug 03

BioMarin Schedules Q2 2026 Results Conference Call and Webcast

Reuters
·
Jul 30

Analysts Conflicted on These Healthcare Names: BioMarin Pharmaceutical (BMRN), Zoetis (ZTS) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Jul 28

BioMarin and n-Lorem Foundation enter research collaboration in ReNU syndrome

TIPRANKS
·
Jul 27

Biomarin Pharmaceutical - and N-Lorem Announce Global Exclusive License to Develop Aso Medicine for Renu Syndrome

THOMSON REUTERS
·
Jul 27

BioMarin, n-Lorem Partner to Develop Antisense Drug Candidate for ReNU Syndrome

Reuters
·
Jul 27

Spruce Biosciences Names Adrian Quartel Chief Medical Officer

Reuters
·
Jul 27

Biomarin Pharmaceutical is Maintained at Buy by Citigroup

Dow Jones
·
Jul 17

FDA Accepts Biomarin Voxzogo Full-approval Application for Children with Achondroplasia

Reuters
·
Jul 13

U.S. Food and Drug Administration Accepts Biomarin's Supplemental New Drug Application for Full Approval of Voxzogo® (vosoritide) for Children with Achondroplasia

THOMSON REUTERS
·
Jul 13

Biomarin Pharmaceutical - FDA Sets Pdufa Target Action Date of Feb. 28, 2027 for Voxzogo Snda

THOMSON REUTERS
·
Jul 13

Is BioMarin Pharmaceutical (BMRN) Still Below Fair Value After Its Russell Index Additions?

Simply Wall St.
·
Jul 08

Biomarin Pharmaceutical is Maintained at Sector Perform by RBC Capital

Dow Jones
·
Jul 08

Jefferies Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Jul 06

Spruce Biosciences names Agnieszka Jurecka vice president, medical affairs

Reuters
·
Jun 22

H.C. Wainwright Reaffirms Their Hold Rating on BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Jun 22